Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1965 2
1966 4
1967 1
1968 1
1969 1
1970 3
1971 2
1972 2
1973 2
1974 3
1975 1
1976 3
1977 1
1978 2
1979 1
1980 1
1984 1
1988 2
1990 1
1991 1
1995 2
1996 2
1997 1
1998 2
1999 1
2004 1
2005 2
2010 2
2011 2
2012 1
2013 4
2014 1
2015 2
2016 1
2017 1
2018 2
2019 4
2020 4
2021 5
2022 6
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Results by year
Filters applied: . Clear all
Page 1
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Among authors: sanchez torres jm. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
Matrix metalloproteinases deregulation in amyotrophic lateral sclerosis.
Sánchez-Torres JL, Yescas-Gómez P, Torres-Romero J, Espinosa OR, Canovas LL, Tecalco-Cruz ÁC, Ponce-Regalado MD, Alvarez-Sánchez ME. Sánchez-Torres JL, et al. J Neurol Sci. 2020 Dec 15;419:117175. doi: 10.1016/j.jns.2020.117175. Epub 2020 Oct 11. J Neurol Sci. 2020. PMID: 33068904 Review.
AZF gene microdeletions in azoospermic-oligozoospermic males.
Lahoz Alonso R, Sienes Bailo P, César Márquez MÁ, Sánchez Torres JC, Albericio Portero JI, Sánchez Parrilla M, Suárez Broto MÁ, Rello Varas L, Izquierdo Álvarez S. Lahoz Alonso R, et al. Among authors: sanchez torres jc. Med Clin (Barc). 2023 Feb 24;160(4):151-155. doi: 10.1016/j.medcli.2022.06.016. Epub 2022 Aug 20. Med Clin (Barc). 2023. PMID: 35999075 English, Spanish.
Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC.
Rogado J, Pozo F, Troule K, Sánchez-Torres JM, Romero-Laorden N, Mondejar R, Donnay O, Ballesteros A, Pacheco-Barcia V, Aspa J, Al-Shahrour F, Alfranca A, Colomer R. Rogado J, et al. Among authors: sanchez torres jm. Cancers (Basel). 2022 Jun 12;14(12):2898. doi: 10.3390/cancers14122898. Cancers (Basel). 2022. PMID: 35740564 Free PMC article.
Excess weight and anti-PD-1 immune checkpoint inhibitor's outcomes in non-small cell lung cancer.
Rogado J, Pozo F, Troulé K, Sánchez-Torres JM, Romero-Laorden N, Mondejar R, Donnay O, Ballesteros A, Pacheco-Barcia V, Aspa J, Al-Shahrour F, Alfranca A, Colomer R. Rogado J, et al. Among authors: sanchez torres jm. Clin Transl Oncol. 2022 Nov;24(11):2241-2249. doi: 10.1007/s12094-022-02887-8. Epub 2022 Jul 23. Clin Transl Oncol. 2022. PMID: 35870091
Nivolumab-induced thyroid dysfunction in patients with lung cancer.
Ramos-Levi AM, Rogado J, Sanchez-Torres JM, Colomer R, Marazuela M. Ramos-Levi AM, et al. Among authors: sanchez torres jm. Endocrinol Diabetes Nutr (Engl Ed). 2019 Jan;66(1):26-34. doi: 10.1016/j.endinu.2018.05.005. Epub 2018 Jun 15. Endocrinol Diabetes Nutr (Engl Ed). 2019. PMID: 29910159 English, Spanish.
[Odontomas, bibliographic review].
Licéaga Escalera C, Sánchez Torres J. Licéaga Escalera C, et al. Among authors: sanchez torres j. ADM. 1976 May-Jun;33(3):55-9. ADM. 1976. PMID: 801233 Review. Spanish. No abstract available.
Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program.
Bernabé-Caro R, Garrido P, García-Campelo R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres JM, Majem M, Diz P, Gordo R, Coca M, de Castro J. Bernabé-Caro R, et al. Among authors: sanchez torres jm. Oncotarget. 2022 Jun 15;13:812-827. doi: 10.18632/oncotarget.28244. eCollection 2022. Oncotarget. 2022. PMID: 35720977 Free PMC article.
76 results